The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days. MAIN OUTCOMES AND MEASURES: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. RESULTS: Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively). CONCLUSIONS AND RELEVANCE: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800968.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF)”
From Safety of Semaglutide (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Furthermore, 2 small randomized clinical trials of liraglutide in patients with HF with reduced EF, 1 of which enrolled patients with recent HF hospitalization, suggested potential harm of liraglutide, although neither trial found statistically significant differences.36,37”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [36]
In the citing paper
“In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.181”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Anand, I. S., Fisher, L. D., Chiang, Y., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 857
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Cited by
Sorted by citations
Items 501–600 of 706
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
Platz, E., Peikert, A., Bozkurt, B., der Schueren, B. V., Butler, J., Lingvay, I., McGuire, D. K., Zannad, F. M., & Sattar, N. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.013 · Cited by 3
Karacabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 3
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure
Sunderland, N. P., Asselin, G., Henry, A., Nelson, C. P., Perreault, L. L., Asselbergs, F. W., Boersma, E. H., Cappola, T. P., Chazara, O., Chutkow, W. A., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5093 · Cited by 3
Self-citationSamaranayake, C. B., Niglas, M., Baxan, N., Kempny, A., Ashek, A., Gatzoulis, M., Price, L. C., Dimopoulos, K., Wilkins, M. R., Wort, S. J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202660 · Cited by 3
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 4
Bhatty, A., Wilkinson, C., Batra, G., Aktaa, S., Smith, A. B., Wahab, A., Chappell, S., Alfredsson, J., Erlinge, D., Ferreira, J., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae086 · Cited by 3
Scherbaum, W. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0234-6 · Cited by 3
Cardiovascular Outcome Trials in Type 2 Diabetes: Food for Thought
Chahade, J. J., Kim, R., & Ussher, J. R. (2021) · Future Cardiology · doi:10.2217/fca-2021-0004 · Cited by 3
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00562-4 · Cited by 3
Role of Liraglutide Use in Patients With Heart Failure
Allam, S. R., Sartaj, S., Moquim, H., Husnain, M. A., Bustos, D., Lakkimsetti, M., Randhawa, A. K., & Gupta, I. (2023) · Cureus · doi:10.7759/cureus.50065 · Cited by 3
Putting More Weight on Obesity Trials in Heart Failure
Harrington, J., Sattar, N. A., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Pagidipati, N. J., Pandey, A., Spall, H. G. C. V., & McGuire, D. K. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00655-z · Cited by 3
Self-citationReza, N., Pellicori, P., & Starling, R. C. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.05.004 · Cited by 3
Song, R., Liu, F., Shi, X., Sun, S., Chen, J., & Gao, H.-M. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae148 · Cited by 3
Treatment options for heart failure in individuals with overweight or obesity: a review
Nasoufidou, A., Stachteas, P., Karakasis, P., Kofos, C., Karagiannidis, E., Klisic, A. N., Popovic, D. S., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2479378 · Cited by 3
The treatment of type 2 diabetes in heart failure
Llano, A., & McKay, G. (2018) · Practical Diabetes · doi:10.1002/pdi.2178 · Cited by 3
Treatment of Diabetes in Patients with Heart Failure
Bowes, C. D., Lien, L. F., & Butler, J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1032-5 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential
Demidova, T. Y., & Kozhevnikov, A. A. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-2-6-12 · Cited by 3
Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials
Birnbaum, Y., Ye, Y., & Bajaj, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.09.007 · Cited by 3
Timmermans, M., Topal, B., Sanches, E. E., de Jongh, F. W., Çağıltay, E., Çelik, A., Ribeiro, R. J. D. S., Parmar, C. D., Ugale, S. M., Proczko, M., et al. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03296-x · Cited by 4
Treatment of Obesity in Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.016 · Cited by 3
Do weight loss interventions challenge the obesity paradox in heart failure?
Yurista, S. R., Eder, R. A., Butsch, W. S., & Luptak, I. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.006 · Cited by 3
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction?
Litwin, S. E., Drazner, M. H., & Russo, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102642 · Cited by 3
Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Lee, M. M. Y., Lean, M. E. J., Sattar, N. A., & Petrie, M. C. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00637-7 · Cited by 2
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 3
Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review
Zhao, J., Lv, S.-S., Qi, L., Cong, X., & Zhang, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s517101 · Cited by 2
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
Scalia, I. G., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Farina, J., Pereyra, M., Lee, K. S. S., Tamarappoo, B. K., Arsanjani, R., & Ayoub, C. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00381-y · Cited by 2
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices
Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Forst, B. J., Allam, M., Mee, X. C., Lim, G. K., Bcharah, G., Barry, T., Farina, J., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15379 · Cited by 2
Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention
Trivedi, M. V., Jadhav, H. R., & Gaikwad, A. B. (2025) · Drug Development Research · doi:10.1002/ddr.70187 · Cited by 2
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 2
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 2
Fussing, F. H., Davodian, L. W., Davodian, D. W., Johansen, N. D., Kumarathurai, P., Modin, D., Sattler, S. M., Larroudé, C. E., Risum, N., Vinther, M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag114 · Cited by 2
Self-citationBeyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists
Xue, C. (2026) · iNew Medicine · doi:10.1002/inm3.70048 · Cited by 2
Kassab, J. T., Drazner, M. H., & Thibodeau, J. T. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag111 · Cited by 3
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers
Chikatimalla, R., Shah, A., Shah, T., Perry, G., Banker, H., Aggarwal, K., & Jain, R. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2660386 · Cited by 3
Ahmed, H. M., Rehman, U. U., Owais, M. A., & Hamza, M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.046 · Cited by 3
Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
Integrating cardioprotective glucose-lowering medications into clinical practice
Mudaliar, S. R. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000142 · Cited by 2
Obata, S., Miyamoto, Y., Slipczuk, L. N., Takagi, H., & Kuno, T. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001430 · Cited by 2
Butler, J., Nair, A. V., & Khan, M. S. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.03.009 · Cited by 2
Ostrominski, J. W., & Vaduganathan, M. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.07.002 · Cited by 2
Obesity in Heart Failure with Reduced Ejection Fraction
Amdahl, M. B., Sundaram, V., & Reddy, Y. N. V. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.06.006 · Cited by 2
Henry, P., Jacqueminet, S., Lemesle, G., Prévost, G., Boccara, Cosson, E., Puymirat, É., Angoulvant, D., Roubille, F., Kownator, S., et al. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.02.012 · Cited by 2
Role of bariatric surgery in patients with advanced heart failure
Kim, D., Kim, I., Youn, J., Kim, J.-J., Jung, M., Choi, J.-O., Kim, D. S. K., Lee, M., Kransdorf, E. P., Chang, D. H., et al. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.05.013 · Cited by 2
Balata, M., Sugiura, A., Hassan, M. N. M., Rady, M., Christoph, M., Ibrahim, K. S. M. H., Becher, M. U., & Youssef, A. A. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02694-5 · Cited by 3
Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial
Butt, J. H., Solomon, S. D., & McMurray, J. J. V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf635 · Cited by 3
Diabète et insuffisance cardiaque : données épidémiologiques et implications thérapeutiques.
Michel Komajda, N. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30256-0 · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement
Basu, A., Patel, D., Winocour, P. H., & Ryder, B. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.283 · Cited by 2
Which drug is best for a patient with type 2 diabetes and heart failure?
Clawson, R., Weidman-Evans, E., & Fort, A. (2021) · JAAPA · doi:10.1097/01.jaa.0000743004.83284.cc · Cited by 2
Stacey, R. B., & Schocken, D. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_21 · Cited by 2
Singh, A. K., & Singh, R. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_12_19 · Cited by 2
Hitchen, S. A., Lan, N. S. R., Fegan, P. G., & Yeap, B. B. (2020) · Internal Medicine Journal · doi:10.1111/imj.15055 · Cited by 2
The Role of GLP-1 Receptor Agonists in Heart Failure
Farkouh, M. E., & Nunes, J. T. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.014 · Cited by 2
Semaglutide in HFpEF and Obesity
Carbone, S., & Patel, K. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102665 · Cited by 2
Alfonso, D. I. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.54 · Cited by 2
The Conundrum of Obesity and Heart Failure
Husain, M., AlQahtani, A., & AlTaweel, M. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2002 · Cited by 1
Henry, P., Jacqueminet, S., Lemesle, G., Prévost, G., Boccara, F., Cosson, E., Puymirat, É., Angoulvant, D., Roubille, F., Kownator, S., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101645 · Cited by 1
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration
Alluri, A. A., MITRA, A., Marepalli, A., Kshitij, R. A. J., Gandhi, N., Prystupa, Y., & Seetharaman, R. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06846-2 · Cited by 1
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
Vest, A. R., & Deswal, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102715 · Cited by 1
Green, C. L., Aladesanmi, O., Chery, G. S., Jackson, L. R., & Thomas, K. L. (2025) · Journal of the National Medical Association · doi:10.1016/j.jnma.2025.11.005 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 9
Ibrahim, R., Han, W., Wang, W. T., Kau, E., Said, N., Forst, B. J., Pham, H. N., Abdelnabi, M. H., Salih, M., Ali, N. B., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044577 · Cited by 2
Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis
Li, X., Liu, G., & Liu, Y. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100064 · Cited by 1
Prevention and Management of Heart Failure Associated with Type 2 Diabetics in Rural Australia
Ross, A. G., Mondal, U. K., Mahmood, S., Astawesegn, F. H., Anyasodor, A. E., Huda, M. M., Thapa, S., Aychiluhm, S. B., Giri, S., Rahman, M. F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010304 · Cited by 1
Fazio, S., & Carlomagno, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1719492 · Cited by 3
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Katsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 2
Lee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 1
Kacmaz, M., Halupka, E., Sultana, I., Delalat, S., El‐Battrawy, I., Khan, M., van Heerebeek, L., & Hamdani, N. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01444-9 · Cited by 1
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Kokura, Y., Kishimori, T., Kato, T., Iwasaki, Y., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113404 · Cited by 1
Androutsopoulou, V. A., Brecher, V., Xanthopoulos, A. V., Avgerinos, D. V., Athanasiou, T., & Magouliotis, D. E. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070305 · Cited by 1
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 1
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Khademi, R., & Shoar, S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00319-y · Cited by 1
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics
Alvarado, A., Martinez-Ponce, J., Ubysz, O., Costa, A., Ataya, L., & Brancheau, D. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110528 · Cited by 1
Yurevich, O., & BORER, J. S. (2017) · InTech eBooks · doi:10.5772/66284 · Cited by 1
Bois, J. P., Gropler, R. J., & Peterson, L. R. (2018) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-018-9444-6 · Cited by 1
Metra, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1006 · Cited by 1
Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes
Rocha, N. A., & Das, S. R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12918 · Cited by 1
Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
Malik, M. E., Andersson, C., Blanche, P., D’Souza, M., Madelaire, C., Zareini, B., Lamberts, M., Kristensen, S. L., Sattar, N. A., McMurray, J. J. V., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02016-z · Cited by 2
Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique
Cosson, E., & Valensi, P. E. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00016-6 · Cited by 1
Akyay, Ö. Z., Sahin, T., Çakmak, Y., Tarkun, İ., Selek, A., Cantürk, Z., Çetinarslan, B., & Karakaya, D. (2022) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_1640_21 · Cited by 2
Liraglutide Mortality Effect on Atrial Fibrillation Patients
Haloot, J., Mahmoud, M., & Badin, A. (2022) · Journal of Atrial Fibrillation and Electrophysiology · doi:10.4022/jafib.20200601 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Zhang, X., & Zhang, H. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2023.100010 · Cited by 1
Demidova, T. Y., Titova, V. V., & Скуридина, Д. В. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-4-23 · Cited by 1
Guerrero, E. L., Hobble, B. A., & Russell, S. D. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102753 · Cited by 1
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?
Ismail, Z., Aboughdir, M., Duric, B., Kaka, S., Chan, J. S. K., Bayatpoor, Y., & Harky, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408376 · Cited by 3
Chen, T., Tseng, C.-J., Li, Y., Lin, Y., Chen, D., Yang, N., Wang, T.-H., Hung, M., & Tsai, M. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02443-6 · Cited by 1
Vignarajah, A., Oro, P., Dahdah, J. E., Vigneswaramoorthy, N. A., Vest, A. R., & Shah, G. V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100676 · Cited by 1
Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
Avogaro, A. (2018) · Diabetes Mellitus · doi:10.14341/dm9816 · Cited by 1
Castillo, G. A., & Morales-Villegas, E. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.12.004 · Cited by 1
Management of Comorbidities in Heart Failure
Ezekowitz, J. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00048-x · Cited by 1
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Metadata
- Authors
- Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., McNulty, S. E., Anstrom, K. J., Shah, M. R., Braunwald, E., Cappola, T. P., & for the NHLBI Heart Failure Clinical Research Network
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Mayo Clinic (US)
- Brigham and Women's Hospital (US)
- University Hospitals of Cleveland (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University (US)
- Tufts University (US)
- National Heart, Lung, and Blood Institute (US)
- Brigham and Women’s Hospital, Boston, Massachusetts
- Corresponding author
- Margulies, Kenneth B.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-02
- Volume
- 316
- Issue
- 5
- Pages
- 500
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5021525
- OpenAlex
- W2505843168
- Cited by
- 706
- References
- 24
- Citations by year
- 2026: 85 · 2025: 99 · 2024: 75 · 2023: 58 · 2022: 46 · 2021: 50 · 2020: 77 · 2019: 68 · 2018: 78 · 2017: 56 · 2016: 13
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL110297, U10HL110342, U10HL084904, U10HL110262, U01HL084861, U10HL110309, U10HL110336, U10HL110302, U10HL110337, U10HL110312, U10HL110338)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, GLP-1 receptor agonists, advanced heart failure, reduced left ventricular ejection fraction, clinical stability, heart failure readmission, mortality, NT-proBNP, myocardial metabolism, type 2 diabetes, cardiac structure and function, 6-minute walk distance, quality of life, subcutaneous injection, cardioprotection
- MeSH terms
- Liraglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Patient Readmission, Quality of Life, Stroke Volume, United States, Odds Ratio, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
